WYC-210 |
| Catalog No.GC60386 |
WYC-210, a Tazarotene derivative, is a retinoid compound with lower anticancer activity.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2131803-93-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
WYC-210, a Tazarotene derivative, is a retinoid compound with lower anticancer activity[1].
WYC-210 (10 μM; 5 days) inhibits cell growth of B16-F1 TRC cells with an inhibition rate of 18.1%[1].
[1]. Cao, Xin, et al. Preparation of the retinoid compound and their application as anticancer agents. WO2017152725A1.
Average Rating: 5 (Based on Reviews and 33 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *